Webinar

Large B cell lymphoma microenvironment archetype profiles

Join us for this webinar featuring work from researchers at The University of Texas MD Anderson Cancer Center that identifies key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T cell therapy.

B cell lymphomas (LBCL) are clinically and biologically heterogeneous lymphoid malignancies with complex microenvironments that are central to disease etiology. Here, Dr. Green's laboratory has employed single-nucleus multiome profiling of 232 tumor and control biopsies to characterize diverse cell types and subsets that are present in LBCL tumors, effectively capturing the lymphoid, myeloid, and non-hematopoietic cell compartments.

Cell subsets co-occurred in stereotypical lymphoma microenvironment archetype profiles (LymphoMAPs) defined by:

• A sparsity of T cells and high frequencies of cancer-associated fibroblasts and tumor-associated macrophages (FMAC)
• Lymph node architectural cell types with naive and memory T cells (LN)
• Activated macrophages and exhausted CD8+ T cells (TEX). Divergent patterns of cell-cell communication underpinned the transcriptional phenotypes of archetype-defining cell subsets resulting in exclusion, support, or suppression of T cells, respectively.

Consistent with this, LymphoMAPs were associated with significantly different clinical outcomes following CD19 chimeric antigen receptor (CAR) T cell therapy.

Featuring

Michael Green, PhD

Vice Chair for Research
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center